Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, Sector 3, MB Road Pushp Vihar, Delhi 110017, India.
University Institute of Pharma Sciences (UIPS), Chandigarh University NH-05, Chandigarh Ludhiana Highway, Mohali Punjab, Pin: 160101, India.
Curr Drug Targets. 2022;23(15):1381-1405. doi: 10.2174/1389450123666220906091432.
The pathogenesis of hepatic diseases involves several cells, which complicates the delivery of pharmaceutical agents. Many severe liver diseases affecting the worldwide population cannot be effectively treated. Major hindrances or challenges are natural physiological barriers and non-specific targeting of drugs administered, leading to inefficient treatment. Hence, there is an earnest need to look for novel therapeutic strategies to overcome these hindrances. A kind of literature has reported that drug safety and efficacy are incredibly raised when a drug is incorporated inside or attached to a polymeric material of either hydrophilic or lipophilic nature. This has driven the dynamic investigation for developing novel biodegradable materials, drug delivery carriers, target-specific drug delivery systems, and many other novel approaches.
Present review is devoted to summarizing receptor-based liver cell targeting using different modified novel synthetic drug delivery carriers. It also highlights recent progress in drug targeting to diseased liver mediated by various receptors, including asialoglycoprotein, mannose and galactose receptor, Fc receptor, low-density lipoprotein, glycyrrhetinic, and bile acid receptor. The essential consideration is given to treating liver cancer targeting using nanoparticulate systems, proteins, viral and non-viral vectors, homing peptides and gene delivery.
Receptors based targeting approach is one such approach that was explored by researchers to develop novel formulations which can ensure site-specific drug delivery. Several receptors are on the surfaces of liver cells, which are highly overexpressed in various disease conditions. They all are helpful for the treatment of liver cancer.
肝脏疾病的发病机制涉及多种细胞，这使得药物制剂的传递变得复杂。许多影响全球人口的严重肝脏疾病无法得到有效治疗。主要的障碍或挑战是天然生理屏障和给药的药物非特异性靶向，导致治疗效果不佳。因此，迫切需要寻找新的治疗策略来克服这些障碍。有一类文献报道，当药物被包裹在亲水性或亲脂性聚合物材料内部或与之结合时，药物的安全性和疗效会大大提高。这推动了对开发新型可生物降解材料、药物输送载体、靶向药物输送系统和许多其他新方法的动态研究。
本综述旨在总结基于受体的肝细胞靶向作用，使用不同修饰的新型合成药物输送载体。它还强调了各种受体介导的靶向病变肝脏药物的最新进展，包括去唾液酸糖蛋白、甘露糖和半乳糖受体、Fc 受体、低密度脂蛋白、甘草次酸和胆酸受体。重点关注基于纳米颗粒系统、蛋白质、病毒和非病毒载体、归巢肽和基因传递的肝癌靶向治疗。
基于受体的靶向方法是研究人员探索开发新型制剂的一种方法，这些制剂可以确保药物的靶向传递。肝脏细胞表面有几种受体，在各种疾病状态下高度过表达。它们都有助于治疗肝癌。
